The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Community Fast Track, 2003NBD Peptides in MPTP Pre-clinical Model
Understanding the mechanism of the disease process of Parkinson's dis and development of effective neuroprotective therapeutic approach to halt the disease progression are of paramount importance. It...
-
Community Fast Track, 2003Biomarker Discovery in Parkinson’s Disease
The primary goal of our studies is to expand our ongoing biomarker discovery program in order to establish biological markers of Parkinson's disease (PD). The imperative to develop effective therapies...
-
Community Fast Track, 2003Mitochondrial Trafficking in Dopaminergic Neuron Injury
Mitochondria are considered to be the "power house" of all cells, including neurons, because they convert food into energy in the form that cells can use. When mitochondria fail, cells typically die...
-
LEAPS, 2003High Resolution Whole Genome Study to Determine Genetic Loci of Parkinson's Disease
The Cox team will leverage Perlegen's high-density array technology and the Mayo Clinic's extensive patient database, clinical expertise and DNA bank to create a genetic map of causes and risk factors...
-
Community Fast Track, 2002Proactive action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a pre-clinical model model of Parkinson's disease
Recently, in mouse studies the peroxisome proliferator-activated receptor-g (PPARg) agonist pioglitazone was shown to be effective in blocking the substantia nigra (SN) cell loss induced by MPTP in a...
-
MJFF Research Grant, 2002Characterization of Alpha Synuclein in Human Fluids & Brain as a Biomarker for Parkinson's Disease
Dr. Michael Schlossmacher and his colleagues at Brigham and Women's Hospital are looking at levels of the protein alpha-synyclein in the blood as a possible biomarker for PD. Mutations in alpha...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.